1
|
GEWALT TABEA, NOH KAWON, MEDER LYDIA. The role of LIN28B in tumor progression and metastasis in solid tumor entities. Oncol Res 2023; 31:101-115. [PMID: 37304235 PMCID: PMC10208000 DOI: 10.32604/or.2023.028105] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 02/16/2023] [Indexed: 06/13/2023] Open
Abstract
LIN28B is an RNA-binding protein that targets a broad range of microRNAs and modulates their maturation and activity. Under normal conditions, LIN28B is exclusively expressed in embryogenic stem cells, blocking differentiation and promoting proliferation. In addition, it can play a role in epithelial-to-mesenchymal transition by repressing the biogenesis of let-7 microRNAs. In malignancies, LIN28B is frequently overexpressed, which is associated with increased tumor aggressiveness and metastatic properties. In this review, we discuss the molecular mechanisms of LIN28B in promoting tumor progression and metastasis in solid tumor entities and its potential use as a clinical therapeutic target and biomarker.
Collapse
Affiliation(s)
- TABEA GEWALT
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
| | - KA-WON NOH
- Institute for Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - LYDIA MEDER
- Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
- Mildred Scheel School of Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| |
Collapse
|
2
|
Xu M, Zhan J, Xie J, Zhu L, Chen L, Luo X, Sheng X, Liu T, Zhang S, Lu Z. MiR-125a-5p inhibits cell proliferation, cell cycle progression, and migration while promoting apoptosis in head and neck cancers by targeting ERBB3. Auris Nasus Larynx 2021; 48:477-486. [PMID: 33077307 DOI: 10.1016/j.anl.2020.10.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 09/22/2020] [Accepted: 10/01/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Head and neck cancer is one of the most common cancer types worldwide. MicroRNAs play a vital regulatory role in the occurrence and development of cancer. The objective of this study is to explore the mechanism of miR-125a-5p in the proliferation, migration and apoptosis of head and neck cancer cells and define its target genes. METHODS The effects of miR-125a-5p on head and neck cancer cells proliferation, cell cycle distribution, apoptosis and migration were evaluated by colony formation, BrdU assay, flow cytometry and transwell assays. The potential target gene of miR-125a-5p was determined by luciferase activity assay and western blot analysis. RESULTS In this study, overexpression of miR-125a-5p significantly inhibited the proliferation of head and neck cancer cells, whereas inhibition of miR-125a-5p enhanced their proliferation. BrdU assay and flow cytometry revealed that miR-125a-5p might inhibit the proliferation of cancer cells by causing cell cycle arrest. Cell apoptosis assay and Transwell assay indicated that miR-125a-5p induced cell apoptosis and inhibited cell migration of cancer cells. Other experiments confirmed that miR-125a-5p could significantly downregulate its expression by binding to ERBB3 to inhibit proliferation and ERBB3 could at least partially mediate the inhibition of miR-125a-5p on the proliferation of head and neck cancer cells. CONCLUSION The findings of this study suggested that the miR-125a-5p/ERBB3 axis might play a role in the proliferation, regulation of cell cycle, migration and apoptosis of head and neck cancer cells, potentially offering a new target for treatments of head and neck cancers.
Collapse
Affiliation(s)
- Mimi Xu
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China; The Second School of Clinical Medicine, Southern Medical University
| | - Jiandong Zhan
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China
| | - Jiaxuan Xie
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China; Shantou University Medical College, Shantou, Guangdong, China
| | - Lijun Zhu
- Department of Oral and Maxillofacial Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China
| | - Liangsi Chen
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China
| | - Xiaoning Luo
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China
| | - Xiaoli Sheng
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China
| | - Tao Liu
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China
| | - Siyi Zhang
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China; The Second School of Clinical Medicine, Southern Medical University.
| | - Zhongming Lu
- Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China; The Second School of Clinical Medicine, Southern Medical University.
| |
Collapse
|
3
|
Cheng C, Mao Q, Shi M, Lu H, Shen B, Xiao T, Yang A, Liu Y. miR-125b prevent the progression of esophageal squamous cell carcinoma through the p38-MAPK signaling pathway. J Gastrointest Oncol 2020; 11:1113-1122. [PMID: 33456986 DOI: 10.21037/jgo-20-546] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Background To examine the clinical significance of miR-125b in esophageal squamous cell carcinoma (ESCC) and to research the effect of miR-125b on the biological function of ESCC cells and the relevant underlying mechanism. Methods The expression of miR-125b in ESCC tissues and cell lines were discovered by RT-PCR assay. The interrelation between miR-125b expression and clinicopathological parameters and the forecasting of ESCC patients were analyzed. CCK-8 method and Transwell methods were used to detect the increased growth, shifting, and irruption of ESCC cells. Bioinformatics analysis was applied to forecast the possible target genes of miR-125b and verified through dual-luciferase reporter gene assay. After that, the expression of p38-MAPK mRNA and protein were found out by RT-PCR and Western blot. Results The expression of miR-125b was down-regulated in ESCC tissues and cell lines (P<0.05). And the expression of miR-125b was closely about tumor differentiation, TNM level, and lymph node metastasis in ESCC patients. The low miR-125b formulation was closely related to rough forecasting in ESCC patients. Large scale expression of miR-125b can effectively decrease the acceleration, shifting, and irrupting strengths of ESCC cells. Bioinformatics analysis showed p38-MAPK was forecasted to be a potential mark of miR-125b, which was confirmed by dual luciferase assay, and extreme expression of miR-125b can stop the expression of p38-MAPK mRNA and protein. Conclusions miR-125b is down-regulated in ESCC. Moreover, its expression level is significant concerning tumor progression and prognosis in patients with ESCC. MiR-125b can stop the high growth and shifting of ESCC cells having p38-MAPK at target.
Collapse
Affiliation(s)
- Chun Cheng
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Qinghua Mao
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Minxin Shi
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Haimin Lu
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Biao Shen
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Ting Xiao
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Aimin Yang
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| | - Yupeng Liu
- Department of Thoracic Surgery, Affiliated Tumor Hospital Nantong University, Nantong, China
| |
Collapse
|
4
|
Wang M, Huang S, Chen Z, Han Z, Li K, Chen C, Wu G, Zhao Y. Development and validation of an RNA binding protein-associated prognostic model for hepatocellular carcinoma. BMC Cancer 2020; 20:1136. [PMID: 33228611 PMCID: PMC7684760 DOI: 10.1186/s12885-020-07625-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 11/10/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is among the deadliest forms of cancer. While RNA-binding proteins (RBPs) have been shown to be key regulators of oncogenesis and tumor progression, their dysregulation in the context of HCC remains to be fully characterized. METHODS Data from the Cancer Genome Atlas - liver HCC (TCGA-LIHC) database were downloaded and analyzed in order to identify RBPs that were differentially expressed in HCC tumors relative to healthy normal tissues. Functional enrichment analyses of these RBPs were then conducted using the GO and KEGG databases to understand their mechanistic roles. Central hub RBPs associated with HCC patient prognosis were then detected through Cox regression analyses, and were incorporated into a prognostic model. The prognostic value of this model was then assessed through the use of Kaplan-Meier curves, time-related ROC analyses, univariate and multivariate Cox regression analyses, and nomograms. Lastly, the relationship between individual hub RBPs and HCC patient overall survival (OS) was evaluated using Kaplan-Meier curves. Finally, find protein-coding genes (PCGs) related to hub RBPs were used to construct a hub RBP-PCG co-expression network. RESULTS In total, we identified 81 RBPs that were differentially expressed in HCC tumors relative to healthy tissues (54 upregulated, 27 downregulated). Seven prognostically-relevant hub RBPs (SMG5, BOP1, LIN28B, RNF17, ANG, LARP1B, and NR0B1) were then used to generate a prognostic model, after which HCC patients were separated into high- and low-risk groups based upon resultant risk score values. In both the training and test datasets, we found that high-risk HCC patients exhibited decreased OS relative to low-risk patients, with time-dependent area under the ROC curve values of 0.801 and 0.676, respectively. This model thus exhibited good prognostic performance. We additionally generated a prognostic nomogram based upon these seven hub RBPs and found that four other genes were significantly correlated with OS. CONCLUSION We herein identified a seven RBP signature that can reliably be used to predict HCC patient OS, underscoring the prognostic relevance of these genes.
Collapse
Affiliation(s)
- Min Wang
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Shan Huang
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Zefeng Chen
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Zhiwei Han
- Department of Chinese Medicine, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Kezhi Li
- Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Chuang Chen
- Department of Chinese Medicine, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Guobin Wu
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China
| | - Yinnong Zhao
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China.
| |
Collapse
|
5
|
Di Palo A, Siniscalchi C, Mosca N, Russo A, Potenza N. A Novel ceRNA Regulatory Network Involving the Long Non-Coding Antisense RNA SPACA6P-AS, miR-125a and its mRNA Targets in Hepatocarcinoma Cells. Int J Mol Sci 2020; 21:ijms21145068. [PMID: 32709089 PMCID: PMC7404396 DOI: 10.3390/ijms21145068] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 07/10/2020] [Accepted: 07/14/2020] [Indexed: 02/07/2023] Open
Abstract
MicroRNAs (miRNA), and more recently long non-coding RNAs (lncRNA), are emerging as a driving force for hepatocellular carcinoma (HCC), one of the leading causes of cancer-related death. In this work, we investigated a possible RNA regulatory network involving two oncosuppressive miRNAs, miR-125a and let-7e, and a long non-coding antisense RNA, SPACA6P-AS (SP-AS), all transcribed from the same locus, with SP-AS in the opposite direction and thus carrying complementary sequences to the miRNAs. In vitro experiments validated the binding of the miRNAs to SP-AS. Then, the boosting of either the miRNAs or SP-AS levels demonstrated their reciprocal inhibition. In addition, overexpression of SP-AS resulted in a reduced silencing activity of miR-125a and let-7e toward their key oncogenic targets, i.e., Lin28b, MMP11, SIRT7, Zbtb7a, Cyclin D1, CDC25B, HMGA2, that resulted significantly upregulated. Finally, the analysis of 374 HCC samples in comparison to 50 normal liver tissues showed an upregulation of SP-AS and a reverse expression of miR-125a, not observed for let-7e; consistently, miR-125a oncogenic targets were upregulated. Overall, the data depict a novel competing endogenous RNA (ceRNA) network, ceRNET, whereby miR-125a can regulate the expression of SP-AS, which in turn regulates the miRNA by competing with the binding to the mRNA targets. We speculate that the unbalancing of any network component may contribute to hepatocarcinogenesis.
Collapse
Affiliation(s)
- Armando Di Palo
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy; (A.D.P.); (C.S.); (A.R.)
| | - Chiara Siniscalchi
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy; (A.D.P.); (C.S.); (A.R.)
| | - Nicola Mosca
- Inserm, BMGIC, U1035, University of Bordeaux, 33076 Bordeaux, France;
| | - Aniello Russo
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy; (A.D.P.); (C.S.); (A.R.)
| | - Nicoletta Potenza
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy; (A.D.P.); (C.S.); (A.R.)
- Correspondence:
| |
Collapse
|
6
|
Proto-oncogene Zbtb7a represses miR-125a-5p transcription in hepatocellular carcinoma cells. Mol Biol Rep 2020; 47:4875-4878. [PMID: 32410140 DOI: 10.1007/s11033-020-05512-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 05/08/2020] [Indexed: 02/07/2023]
Abstract
Zbtb7a is a transcription factor whose dysfunction is correlated to the development of several types of cancer, including hepatocellular carcinoma (HCC). It generally acts as a repressor of transcription downregulating the expression of several target genes including oncosuppressors ARF and Rb. In this study, Zbtb7a was found to suppress the expression of miR-125a, an oncosuppressive miRNA that is often downregulated in HCC. This effect is mediated by the binding of the transcription factor to a regulatory sequence in the promoter of the transcription unit of miR-125a located 14 bp upstream of the transcription start site. Consistent with this observation, the analysis of 370 HCC samples showed an upregulation of Zbtb7a compared to 50 normal liver tissues and a reverse correlation with miR-125a expression. These data suggest that miR-125a may support the oncogenic potential of Zbtb7a.
Collapse
|
7
|
Yang M, Tang X, Wang Z, Wu X, Tang D, Wang D. miR-125 inhibits colorectal cancer proliferation and invasion by targeting TAZ. Biosci Rep 2019; 39:221372. [PMID: 31782506 PMCID: PMC6911154 DOI: 10.1042/bsr20190193] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Revised: 11/06/2019] [Accepted: 11/28/2019] [Indexed: 02/07/2023] Open
Abstract
Colorectal cancer (CRC) is the third most common malignant tumor worldwide and is a serious threat to human health. MicroRNAs (miRNAs) play a key role in oncogenesis and cancer progression. MiRNA-125 (miR-125) is an important miRNA that is dysregulated in several kinds of cancers. Thus, we investigated the expression and effects of miR-125 and Transcriptional co-activator with PDZ-binding motif (TAZ) for a better understanding of the underlying mechanism of tumor progression in CRC, which may provide an emerging biomarker for diagnosis and treatment of CRC. We measured the expression levels of miR-125 in CRC tissues, adjacent tissues, and cell lines (e.g. HCT116, SW480, FHC) by quantitative real-time polymerase chain reaction (qRT-PCR). The effect of miR-125 on proliferation and invasion in CRC cells was detected by Cell Counting Kit-8 (CCK-8), clone formation assay, and transwell assay. Western blotting and qRT-PCR were used to investigate the expression of TAZ after knocking down miR-125 in HCT116 cells or overexpressing miR-125 in SW480 cells. MiR-125 was significantly down-regulated in CRC compared with pericarcinomatous tissue from 18 patients. An miR-125 inhibitor promoted CRC cell proliferation and invasion, while miR-125 mimic had the opposite effect. Moreover, we found that TAZ was an miR-125 target and the siRNA knockdown of TAZ could reverse the effect of the miR-125 inhibitor on proliferation and invasion in HCT116 cells. The present study shows that miR-125 suppresses CRC proliferation and invasion by targeting TAZ.
Collapse
Affiliation(s)
- Meiyuan Yang
- Department of General Surgery, The Second Xiangya Hospital of Central South University, Renmin Road No.139, Changsha 410001, China
| | - Xiaoli Tang
- Department of General Surgery, The Second Xiangya Hospital of Central South University, Renmin Road No.139, Changsha 410001, China
| | - Zheng Wang
- Department of General Surgery, Clinical Medical College of Yangzhou University, Huaihai Road No.7, Yangzhou 225001, China
| | - Xiaoqing Wu
- Department of General Surgery, Clinical Medical College of Yangzhou University, Huaihai Road No.7, Yangzhou 225001, China
| | - Dong Tang
- Department of General Surgery, Clinical Medical College of Yangzhou University, Huaihai Road No.7, Yangzhou 225001, China
- Department of General Surgery, Medical College, Yangzhou University, Northern Jiangsu Province Hospital, General Surgery Institute of Yangzhou University, Nantong Road No.98, Yangzhou 225001, China
- Correspondence: Daorong Wang () or Dong Tang ()
| | - Daorong Wang
- Department of General Surgery, Clinical Medical College of Yangzhou University, Huaihai Road No.7, Yangzhou 225001, China
- Department of General Surgery, Medical College, Yangzhou University, Northern Jiangsu Province Hospital, General Surgery Institute of Yangzhou University, Nantong Road No.98, Yangzhou 225001, China
- Correspondence: Daorong Wang () or Dong Tang ()
| |
Collapse
|
8
|
Tian N, Shangguan W, Zhou Z, Yao Y, Fan C, Cai L. Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma. J Cancer 2019; 10:6074-6087. [PMID: 31762817 PMCID: PMC6856568 DOI: 10.7150/jca.33421] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Accepted: 08/24/2019] [Indexed: 12/11/2022] Open
Abstract
Chemoresistance remains a big challenge in hepatocellular carcinoma (HCC) treatment. Several studies indicated that RNA-binding protein Lin28B serves an oncogenic role in HCC, but its activity in HCC chemotherapy has never been assessed. In this study, we found that overexpression of Lin28B significantly increased the paclitaxel chemoresistance in two different HCC cells lines while silencing Lin28B reduced the chemoresistance in paclitaxel-resistance HCC cells. Curcumin, a natural anti-cancer agent, increased the sensitivity of HCC cells to paclitaxel through inhibiting NF-κB stimulated Lin28B expression both in vitro and in vivo. Furthermore, by analyzing TCGA (The Cancer Genome Atlas) LIHC (liver hepatocellular carcinoma) and GSE14520 databases, we found that Lin28B was highly upregulated in HCC tissue compared with that in normal tissue and associated with α‑fetoprotein levels, and that patients with Lin28B higher expression had a significant shorter overall survival time than those with Lin28B lower expression. Our data reveal that Lin28B may serve as a predictive biomarker and a treatment target to reverse HCC chemotherapy resistance in future clinical practice.
Collapse
Affiliation(s)
- Nan Tian
- Institute of Molecular Medicine, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Wenbing Shangguan
- Institute of Molecular Medicine, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Zuolin Zhou
- Institute of Molecular Medicine, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Yao Yao
- Institute of Molecular Medicine, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Chunlei Fan
- Institute of Molecular Medicine, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Lijun Cai
- Department of gastroenterology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| |
Collapse
|
9
|
Russo A, Potenza N. Antiproliferative Activity of microRNA-125a and its Molecular Targets. Microrna 2018; 8:173-179. [PMID: 30394225 DOI: 10.2174/2211536608666181105114739] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 10/18/2018] [Accepted: 10/29/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND MicroRNA-125a is present in all animals with bilateral symmetry and displays a conserved nucleotide sequence with a section of 11 bases including the seed region that is identical in all considered species. It primarily downregulates the expression of LIN28, thereby promoting cell differentiation and larval phase transitions in nematodes, mammals and insects. OBJECTIVE In this review, we focus on the cellular control of miR-125a expression and its antiproliferative activity. RESULTS In mammalians, microRNA-125a is present in most adult organs and tissues in which it targets proteins involved in the mitogenic response, such as membrane receptors, intracellular signal transducers, or transcription factors, with the overall effect of inhibiting cell proliferation. Tissue levels of miR-125a generally raise during differentiation but it is often downregulated in cancers, e.g. colon, cervical, gastric, ovarian, lung, and breast cancers, osteosarcoma, neuroblastoma, glioblastoma, medulloblastoma, retinoblastoma and hepatocellular carcinoma. CONCLUSION The antiproliferative activity of miR-125a, demonstrated in many cell types, together with the notion that this miRNA is downregulated in several kinds of cancers, give a substantial support to the concept that miR-125a plays an oncosuppressive role.
Collapse
Affiliation(s)
- Aniello Russo
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy
| | - Nicoletta Potenza
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy
| |
Collapse
|
10
|
Xia RB, Wang HY, Dai D, Dong TM, Wang HP, Zou SL, Zhang J. MiR-128-3p increases sensitivity of hepatoma cells to oxaliplatin by targeting Lin28B. Shijie Huaren Xiaohua Zazhi 2018; 26:1748-1757. [DOI: 10.11569/wcjd.v26.i30.1748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM To investigate the effect of miR-128-3p on the sensitivity of hepatocellular carcinoma (HCC) cells to oxaliplatin, and explore the underlying mechanism.
METHODS qRT-PCR was used to detect the expression of miR-128-3p and Lin28B in human liver cells (HL-7702) and human HCC cells (BEL-7402 and Hep-3B). BEL-7402 and Hep-3B cells as well as oxaliplatin resistant BEL-7402 and Hep-3B cells in logarithmic growth phase were randomly divided into a miR-128-3p mimic group (transfected with miR-128-3p mimics), a miR-NC group (untransfected cells), a Lin28B-3ʹ UTR WT group (psiCHECK2-Lin28B-3ʹUTR WT and miR-128-3p co-transfection), a Lin28B-3ʹ-UTR MUT (psiCHECK2-Lin28B-3ʹ UTR MUT and miR-NC co-transfection), a miR-128-3p + Lin28B group (miR-128-3p and Lin28B co-transfection), a si-Lin28B group (transfected with si-Lin28B) and a si-NC (transfected with silencing control). All cells were transfected via liposomes. The survival rate and viability of each group were detected by MTT assay, and the protein expression was detected by Western blot.
RESULTS Compared with human hepatocytes, the expression of miR-128-3p in HCC cells (BEL-7402 and Hep-3B) was significantly decreased, and the expression of Lin28B was significantly increased. Overexpression of miR-128-3p or silencing Lin28B increased the sensitivity of HCC cells to oxaliplatin. Lin28B is a target of miR-128-3p, and overexpression of Lin28B could reverse the effect of miR-128-3p in increasing the sensitivity of HCC cells to oxaliplatin.
CONCLUSION MiR-128-3p can increase the sensitivity of HCC cells to oxaliplatin possibly via a mechanism related to targeting Lin28B, suggesting that miR-128-3p could be used as a potential target for treatment of oxaliplatin resistance.
Collapse
Affiliation(s)
- Ru-Bing Xia
- Department of Pharmacy, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| | - Hong-Ying Wang
- Department of Pharmacy, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| | - Dan Dai
- Department of Pharmacy, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| | - Tao-Ming Dong
- Department of Oncology, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| | - He-Ping Wang
- Radiation Therapy Center, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| | - Si-Lu Zou
- Department of Pharmacy, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| | - Jian Zhang
- Department of Pharmacy, the Second People's Hospital of Jingdezhen, Jingdezhen 333000, Jiangxi Province, China
| |
Collapse
|